news

Experimental drug targets cancers associated with Epstein-Barr virus

An experimental drug is reported to have potential to treat Epstein-Barr virus related lymphomas by counteracting the cancer-promoting mechanisms of LMP2A…

EBV

An experimental drug has shown potential in treating tumour development and metastasis for Epstein-Barr virus (EBV) related lymphomas.

EBV does not cause cancer, however infection with this virus means an increased susceptibility to some cancers.

Researchers form the American Society for Microbiology report a new drug, TAK-659, that works by targeting EBV-positive tumours. The virus is so common that almost every individual in the US has been infected by the time they are in their twenties. Infection by the virus can cause mononucleosis, however many people remain asymptomatic their entire lives. An increase of other cancers, including stomach and nasopharyngeal cancers have also been associated with EBV.

 

Reserve your FREE place

 


Reduce preclinical failures with smarter off-target profiling

24 September 2025 | 15:00PM BST | FREE Webinar

Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.

What you’ll learn:

  • Approaches for prioritizing follow-up studies and refining risk mitigation strategies
  • How to interpret hit profiles from binding and functional assays
  • Strategies for identifying organ systems at risk based on target activity modulation
  • How to use visualization tools to assess safety margins and compare compound profiles

Register Now – It’s Free!

 

In mouse models the drug inhibited tumour development and metastasis for EBV-related lymphomas.

“In certain circumstances the virus can contribute to cancer,” said the study’s lead author, microbiologist Dr Richard Longnecker at the Northwestern University Feinberg School of Medicine, in Chicago.

Infections by EBV may increase the growth of B lymphocytes, which then results in lymphomas. EBV also encode LMP2A, a protein that can hijack the cell signalling mechanism of the B cells it infects. In this study, mice had been genetically modified to express LMP2A in B cells that promoted lymphoma development.

The tyrosine kinase inhibitor TAK-659 counteracted the cancer-promoting mechanisms of the LMP2A protein. The drug was shown to kill tumour cells, promoting apoptosis in them, but left host cells unaffected. The drug also stopped spread of the tumour cells into bone marrow.

Takeda Pharmaceuticals, the company developing the drug, has launched phase I clinical trials.

The researchers suggest that the drug can be used independently, or as part of combination therapy with other cancer treatments, such as immunotherapies.

The results of the study were published in mSphere.

Leave a Reply

Your email address will not be published. Required fields are marked *